此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

针对青少年复发性/进展性非典型畸胎样横纹肌样瘤(ATRT)新型疗法的研究

2026年11月5日 更新者:Sabine Mueller, MD, PhD

针对儿童、青少年及年轻成人复发性/进展性非典型畸胎样横纹肌样瘤(ATRT)新型疗法的平台研究

This is a multi-treatment arm study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC).The study will assess the safety and efficacy of novel therapies and combinatorial strategies for participants with recurrent or progressive ATRT.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To assess efficacy of each treatment arm based on arm-specific endpoints. II. To evaluate the safety and tolerability of each treatment arm for patients with recurrent/progressive ATRT.

EXPLORATORY OBJECTIVES:

I. To collect additional treatment arm-specific safety and tolerability information as applicable.

II. To determine additional treatment arm-specific time-to-event endpoints. III. To assess the correlations between methylation-based subgroups and objective response and outcome measures.

IV. To collect biologic samples (tumor, blood, CSF) for future biomarker discovery.

V. Additional treatment arm-specific exploratory objectives may be added in each interventional arm.

OUTLINE: Participants will enroll onto a treatment arm as treatment arms open for enrollment. Participants who are taken off treatment on one trial arm for progression or toxicity may enroll on a new treatment arm, if arm-specific eligibility criteria are met. If the study is opened at the treating institution, participants will be followed under the Pediatric Neuro-oncology Consortium (PNOC) COMP protocol until death or withdrawal from study.

研究类型

介入性

注册 (估计的)

29

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:PNOC Operations Office
  • 电话号码:415-502-1600
  • 邮箱:PNOC035@ucsf.edu

学习地点

    • California
      • San Francisco、California、美国、94143
        • 招聘中
        • University of California, San Francisco
        • 首席研究员:
          • Sabine Mueller, MD, PhD, MAS
        • 接触:
      • San Francisco、California、美国、94143
        • 尚未招聘
        • University of California, San Francisco
        • 首席研究员:
          • Sabine Mueller, MD, PhD
        • 接触:
        • 接触:
    • Maryland
      • Baltimore、Maryland、美国、21218
        • 招聘中
        • John Hopkins Hospital
        • 接触:
        • 首席研究员:
          • Kenneth Cohen, MD
    • Washington
      • Seattle、Washington、美国、98105
        • 招聘中
        • Seattle Children's Hospital University of Washington, Seattle
        • 接触:
        • 首席研究员:
          • Erin Crotty, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 39年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • In addition to the below, investigators are to refer to arm-specific inclusion criteria in the appendix.

    • Participants must have a pathologic diagnosis of central nervous system (CNS) ATRT, with confirmation of SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1 (SMARCB1) (INI1) loss by immunohistochemistry (IHC) and/or biallelic loss of function of SMARCB1 by molecular report. Loss of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 (SMARCA4) as confirmed by IHC or molecular report is also acceptable but requires study chair approval.
    • Participants must have confirmation of methylation report, co-enrollment on PNOC-030 or sufficient tumor tissue available for methylation-based subgrouping
    • Participants must have recurrent or progressive ATRT.
    • Participants age must be ≥1 and ≤ 39 years at the time of study enrollment. Please refer to arm specific inclusion criteria for potential variations in lower age eligibility limit.
    • Prior Therapy: Participants must have fully recovered from the acute effects of prior anti-cancer therapy, and the following wash-out periods need to be observed prior to enrollment:
  • Systemic myelosuppressive therapy: ≥ 21 days after the last dose (42 days for nitrosoureas or mitomycin C).

  • Intrathecal/intraventricular chemotherapy: > 7 days after the last dose.

  • Small molecule/targeted/biologic agent: ≥ 7 days after the last dose.

  • Monoclonal antibodies: ≥ 21 days after the last dose. Other non-myelosuppressive anti-cancer agents: ≥ 3 drug half-lives after the last dose.

  • CAR-T cell therapy (systemic or intraventricular): > 21 days.

    • Previous radiotherapy. Participants will be eligible following radiotherapy, if they meet the following criteria:

  • Previous craniospinal or total body radiotherapy: Participants must have received their last fraction ≥ 12 weeks prior to enrollment and have evidence of progressive/recurrent evaluable disease post radiation.

  • Previous focal radiotherapy to target lesions: Participants must have received their last fraction to target lesions ≥12 weeks prior to enrollment and have evidence of progressive/recurrent evaluable disease post radiation; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression.

  • Focal radiotherapy to non-target lesions: Participants may have received radiotherapy to nontarget lesions as long as the last fraction was > 14 days prior to enrollment. Participants must have at least one non-irradiated lesion that is evaluable for response.

    • Performance Score: Karnofsky ≥ 50 for participants > 16 years of age and Lansky ≥ 50 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
    • Corticosteroids: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment. Please also refer to arm-specific inclusion criteria for potential variations in steroid limitations.
    • Organ Function Requirements.

Adequate Bone Marrow Function Defined as:

  • Peripheral absolute neutrophil count (ANC) ≥ 750/mm3
  • Platelet count ≥ 75,000/cubic millimeters (mm3) (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).

Adequate Renal Function Defined as:

  • Serum creatinine ≤ 1.5 Upper Limit Normal (ULN) based on age and gender

Adequate Liver Function Defined as:

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age; in presence of Gilbert's syndrome, total bilirubin < 3 x ULN or direct bilirubin < 1.5 x ULN
  • Alanine aminotransferase (ALT) ≤ 3 x ULN
  • Aspartate aminotransferase (AST) ≤ 3 x ULN

Adequate Neurologic Function Defined as:

  • Participants with seizure disorder may be enrolled if well controlled. See arm-specific recommendations for potential interactions between anticonvulsant agent(s) with study drug.

    • Effect on the developing human fetus Recommendations on the potential effect of interventional agents on the developing human fetus will be specified in each study arm's details of therapeutic agents. Unless otherwise specified, the effects of study interventions should be considered potentially teratogenic. Thus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment and four months after its completion. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, or should a male participant's partners become pregnant during study participation, they should inform the treating physician immediately.
    • A legal parent/guardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.
    • Participants must enroll on Pediatric Neuro-oncology Consortium (PNOC) COMP if PNOC COMP is open to accrual at the enrolling institution.

Exclusion Criteria:

  • Evidence of synchronous tumors or other extra-CNS malignancy
  • Participants who are receiving any other investigational agents
  • Participants who are currently receiving other anti-cancer agents
  • Participants with uncontrolled infection or other uncontrolled systemic illness
  • Female participants of childbearing potential who are pregnant or breast-feeding. Female participants of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy and throughout study treatment.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition as the intended treatment regimen, as detailed in that arm's treatment description.

Arm A

Inclusion Criteria:

  • Subjects must meet all inclusion criteria for the overall study.
  • Patients must be evaluable per Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria for medulloblastoma and other leptomeningeal seeding tumors to be evaluated for the primary endpoint (Warren et al. 2018); patients with evaluable but non-measurable disease, including leptomeningeal disease or positive CSF cytology only are eligible.

Patients with recurrent or progressive ATRT who receive surgery only for their disease progression and do not have evaluable disease may be eligible for study treatment but would not be included towards the primary efficacy endpoint (to be discussed with study chairs).

  • Subjects must be able to swallow intact capsules.

  • Adequate Metabolic Function Defined as:

    • Non-fasting glucose ≤ 140 milligrams per deciliter (mg/dL) without the use of antihyperglycemic agents.
    • If non-fasting glucose > 140 mg/dL, a fasting glucose should be done. If fasting glucose ≤ 125 mg/dL without the use of antihyperglycemic agents, participant will meet adequate metabolic function criteria.
    • Triglycerides of < 300 mg/dl and total cholesterol of < 300 mg/dl - can be on lipid lowering medications as needed to achieve.
  • Adequate Cardiac Function Defined as:

    • Electrocardiogram (ECG) must be obtained to verify the Corrected QT Interval (QTC). If an abnormal reading is obtained, the ECG should be repeated in triplicate.
    • QTC < 470 millisecond (msec)

Arm A

Exclusion Criteria:

In addition to not meeting any of the exclusion criteria of the overall study, participation on arm A will also require that subjects do not meet any of the following:

  • Previous exposure to gemcitabine or paxalisib
  • Concomitant use of an antihyperglycemic agent (e.g. metformin)
  • Chronic diarrhea greater than Grade 2

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment Arm A: Phase I

Participants will receive a combination of gemcitabine and paxalisib with starting dose, 1,200mg/m2 gemcitabine and 15mg/m2 paxalisib (phase I). If this dose level is tolerated, it will be confirmed as the RP2D. However, if the dose limiting toxicity (DLT) is not tolerated, the RP2D will be set at the highest dose level tolerated by the previous group.

Given IV

Cerebral Spinal Fluid (CSF) will be collected for research

Perform blood draw

Undergo imaging procedure

Given orally (PO)

Undergo biopsy

实验性的:Treatment Arm A: Efficacy (Phase II)

All participants will receive a combination of gemcitabine and paxalisib over a 28-day cycle, for up to 24 cycles or until they meet criteria to stop treatment, whichever comes first. Gemcitabine will be administered via infusion on days 1, 8, and 15 of each cycle, while paxalisib will be taken daily throughout each cycle.

Given IV

Cerebral Spinal Fluid (CSF) will be collected for research

Perform blood draw

Undergo imaging procedure

Given orally (PO)

Undergo biopsy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Arm A (Phase I): Proportion of participants who experience dose-limiting toxicity (DLT)
大体时间:up to 28 days

Tolerability is defined as the proportion of participants receiving at least one dose of combination gemcitabine and paxalisib with a reported dose-limiting toxicity (DLT) during cycle 1 for all participants in Phase I.

up to 28 days
Arm A (Phase I): Recommended Phase 2 Dose (RP2D) (Phase I)
大体时间:up to 28 days

The confirmed RP2D of combination gemcitabine and paxalisib implemented for participants enrolled in Phase II will be reported.

up to 28 days
Arm A (Phase II): Rate of Clinical Benefit
大体时间:up to 2 years (24 cycles)

Assess the efficacy of combination gemcitabine and paxalisib for participants in Phase II. Clinical Benefit rate (CBR) is defined as complete response (CR) + partial response (PR) + stable disease (SD), where SD is sustained over 4 months.

up to 2 years (24 cycles)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sabine Mueller, MD, PhD、University of California, San Francisco
  • 学习椅:Ashley Margol, MD, MS、Children's Hospital Los Angeles

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月17日

初级完成 (估计的)

2035年12月31日

研究完成 (估计的)

2036年12月31日

研究注册日期

首次提交

2026年2月25日

首先提交符合 QC 标准的

2026年2月25日

首次发布 (实际的)

2026年3月3日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅